All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2017; the latest 2025-03-28.
From the record
Biodesix, Inc.'s filings since 2017 show 1 warning event: a notice about its exchange listing (8-K item 3.01, the latest 2025-03-28) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+23.8% a year over 7 filed years; profitable in 0 of 7.
From the record
Biodesix, Inc.'s 7 filed years say what it did: revenue went from $25 million in fiscal 2019 to $88 million in fiscal 2025, up 23.8% a year; it rose in 5 of 6 years; the deepest fall was 30% from fiscal 2021 to fiscal 2022; net income was positive in 0 of 7 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 1.1/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Biodesix, Inc.'s shareholder treatment is put at 1.1 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 11% of 24 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
Leverage 103%: owes 103¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Biodesix, Inc.'s shareholders' equity was below zero, so the profit on it is not read. Leverage: it owed about 103 cents per dollar of assets, and net share issuance: its share count grew 16.7% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 48% of 24 in its family; net margin -39.8%.
From the record
Biodesix, Inc.'s standing among 24 graded names in its industry family: revenue of $88 million in fiscal 2025 ranks in the bottom 41% by size; a net margin of -39.8% ranks in the bottom 31%; revenue growth of 32.3% a year over the last 3 filed years ranks in the top 28% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
top 36% of 17 in its family for leadership; chief executive since 2020.
From the record
Biodesix, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Hutton, Scott (President & CEO, as filed), filing under that title since 2020-10-27, 6 years (top 32% of its family); the 12 officers and directors filing in the last fifteen months have been on the record a median of 6 years (top 37%); 2 officer or director changes were reported on Form 8-K since 2023-11-13, against the 12 people in charge now (top 39%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
bottom 21% of 24 in its family for room to expand.
From the record
Biodesix, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $19 million against debt of $50 million leaves -35.4% of its assets as net cash, bottom 6% of its family; cash from operations less capital spending is -26.6% of revenue (bottom 31%); research spending of 13.6% of revenue (bottom 25%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 45% of 23 in its family for growth drivers.
From the record
Biodesix, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 32.3% a year over the last three filed years against 23.8% over all 7, speeding up (top 7% of its family); the newest year grew 24.1% (top 24%); research spending grew -2.9% a year (bottom 42%); capital spending grew -57.2% a year (bottom 7%) (its annual reports). Biodesix, Inc. reported 2 product lines in fiscal 2025: Diagnostic Tests at $79 million (90%), Development Services at $9 million (11%); 2 of 2 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 37% of 20 in its family for expectations against reality.
From the record
Biodesix, Inc.'s newest year against its own record: revenue of $88 million in fiscal 2025 came in 9.2% below the $97 million its prior three years' pace pointed to (bottom 38% of its family); net income of $35 million against a prior three-year average of $54 million (top 27%); a net margin of -39.8% against losses larger than its revenue before (top 22%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made